Quantum BioPharma Ltd. Ordinary Shares - Class B (Sub Voting) QNTM 深 滬
已收盤 10-31 16:00:00 美东时间
11.07
-1.470
-11.72%
華盛通- 最 高12.46
- 今 開12.21
- 成交量 8.83万股
- 最 低 11.00
- 昨 收 12.54
- 總市值 4225.31万
- 52周最高 38.25
- 市盈率 靜 --
- 換手率 2.31%
- 52周最低 2.70
- 委 比 97.80%
- 總股本 381.69万
- 歷史最高 909.5234
- 量 比 1.36
- 振 幅 11.64%
- 歷史最低 2.89
- 每 手 1
- 風險率 7.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
Quantum BioPharma’s licensee, Unbuzzd Wellness, announces a Reg D 506(c) offering targeting $5 million to expand distribution and retail sales of its hangover-relief beverage, unbuzzd. An investor webinar on Oct 30, 2025, will discuss the investment opportunity, leadership, and growth strategy. Unbuzzd, scientifically proven to accelerate alcohol metabolism and reduce hangover symptoms, has gained traction due to its innovation and market relevan...
10-23 12:15
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
Quantum BioPharma Ltd. announced the expiration of 53,147 warrants issued to hedge funds and investment funds as part of a 2020 financing. The company reaffirmed October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders. Each CVR entitles holders to a portion of net proceeds from ongoing litigation against financial institutions, seeking over $700 million in damages for alleged...
10-20 12:30
Quantum BioPharma Denies Unsubstantiated Securities Investigation Allegations, Vows Legal Action Against Law Firms
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
10-14 20:25
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
Quantum BioPharma Ltd. announced that October 27, 2025, will be the record date for distributing contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares. Each CVR entitles the holder to a pro rata portion of 10% to 50% of the net proceeds from its ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million. Payments under CVRs are contingent on recei...
10-03 11:00
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
Quantum BioPharma Ltd. announced receipt of two final reports for its Lucid-MS drug targeting Multiple Sclerosis, advancing its IND application for a phase-2 clinical trial. The company expressed excitement over the potential of Lucid-MS to address demyelination in MS.
10-02 11:57
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis (MS) expert, as a clinical advisor for its Lucid-MS program, a drug aimed at inhibiting demyelination in MS. Dr. Antel will advise on the clinical development of Lucid-MS, including designing efficacy trials. His extensive expertise in MS research and his interdisciplinary experience are expected to significantly advance the drug's progress toward a Phase 2 c...
10-01 11:50
Quantum BioPharma Announces Shareholder Meeting Results
The latest update is out from Quantum Biopharma ( ($TSE:QNTM) ). On September 2...
09-29 19:57
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
Quantum BioPharma Ltd. announced the results of its annual general and special meeting of shareholders held on September 26, 2025. All nominated directors were elected with over 99% support. Shareholders reappointed MNP LLP as the Company’s auditor and approved the issuance of up to 56 additional Class A Multiple Voting Shares, with 90.992% voting in favor.
09-29 11:40
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
Quantum BioPharma Ltd. has received a Product License from Health Canada for its natural health product, Qlarity, allowing its sale in Canada. Qlarity is recommended for energy production, metabolism support, fatigue reduction, and cognitive performance enhancement. The company has also licensed a similar product, unbuzzd™, for the U.S. market. Quantum BioPharma is focused on developing innovative biotech solutions for neurodegenerative and metab...
09-18 12:10
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar on September 16, 2025, to discuss its Reg D 506(c) investment opportunity for the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. The webinar will feature Unbuzzd CEO John Duffy and other executives who will review the science and clinical trial results, as well as the...
09-12 11:50
